Our dedicated regulatory support services encompass compliance with international guidelines, correct documentation preparation and submission, and continuous communication with regulatory authorities on your behalf. We are committed to effectively managing these regulatory requirements to guide your products seamlessly from research and development to successful market approval and beyond.
What can we do for you?
The field of biological medicinal products is particularly diverse. Our team has been involved in the development and registration of amongst other several vaccines, ATMPs (advanced therapy medicinal products), antibodies and biosimilars.
We provide regulatory support for the development and marketing of your biological/biotech product at any step in the development and registration process; from guiding strategic development decisions, requesting scientific advice, applying for ATMP or biosimilar classification at the EMA or FDA, to assisting in authoring and/or reviewing of your registration dossiers.
Approach & Expertise
Learn how we can support you in meeting your business goals
- Our lean and powerful team with degrees in pharmacy, chemistry, biology, or related studies strive to be of added value to you. Our short reporting lines enable the most efficient road to your success.
- Having one point of contact from our experts backed by the team’s collective knowledge and resources we give reliable advice and execute projects seamlessly.
- At Starodub, consistency and assurance of quality are vital. A quality management system has been implemented and we adhere to GxP and ISO 9001/13485.
Questions from our clients
FAQ Section
According to the definition by the EMA, a biosimilar is “a biological medicine highly similar to another already approved biological medicine”. While biosimilars are not identical to their reference products, they exhibit no clinically meaningful differences in terms of safety, purity, and potency. They are developed to be comparable versions of the original biologic, produced by different manufacturers. Biosimilars undergo rigorous testing to demonstrate similarity to the reference product through analytical, pharmacokinetic, pharmacodynamic, and clinical studies.
ATMPs are regulated under specific regulatory frameworks tailored to their unique characteristics. In the EU, for example, ATMPs are regulated under Regulation (EC) No 1394/2007. In addition, a specific scientific advice procedure for the classification of ATMPs is in place. And the EMA has published guidance on the use of a risk-based approach for determining and justifying the extent of data in the various sections of the MAA dossier.
Especially for ATMPs, early pre-submission communication with regulators is essential. The FDA’s Center for Biologics Evaluation and Research (CBER) also recommends communication during early product development with their Office of Therapeutic Products (OTP).